What is US 8,158,616 B2 for baricitinib?
US 8,158,616 B2 is a granted U.S. patent that covers certain claimed subject matter related to baricitinib. If you are trying to find the exact patent document (including the PDF and the full claim text), the most reliable route is to use the patent number to pull the official record from a patent database.
Where can I download the US 8,158,616 B2 patent PDF?
The quickest way to get the PDF is to search by the patent number “US8158616” (or “US 8,158,616”) in a patent viewer/download site. Common options are:
- Google Patents (often provides a “Download PDF” link)
- The USPTO’s patent search tools (may also link to documents, depending on the record)
How do I verify the PDF really matches baricitinib?
After you open the PDF, check the following in the front matter:
- Title/abstract referencing baricitinib (or the chemical class/name used in the patent)
- Applicant/assignee (often tied to the original developer of baricitinib)
- Claim language that mentions baricitinib or the specific chemical structure/identifier used
Who owns the patent and what company is tied to it?
Ownership can change over time due to assignments. The assignee listed in the patent document’s bibliographic data is the best single source for the formal chain at the time of publication/grant. If you share the assignee name you see on the PDF, I can help you cross-check whether it aligns with major baricitinib holders and related filings.
What do people usually search next after finding a baricitinib patent?
Typical follow-up searches include:
- “When does US 8,158,616 B2 expire?”
- “Is this patent still enforceable or under litigation?”
- “What claims cover baricitinib dosage/formulation/use?”
- “Does this patent overlap with other baricitinib patents or exclusivity periods?”
If you want, I can pull the exact match
If you tell me which site you’re using (Google Patents, USPTO, Lens.org, etc.) or paste the title/assignee line from the PDF cover page, I can help confirm you have the right US 8,158,616 B2 baricitinib document and point you to the right related patents/exclusivity.